Safety and immunogenicity of <scp>mRNA COVID</scp> ‐19 vaccine in inpatients with muscular dystrophy-Reference-Cited by-同舟云学术

Safety and immunogenicity of mRNA COVID ‐19 vaccine in inpatients with muscular dystrophy

Published:2022-12-19 Issue:2 Volume:67 Page:117-123
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle and Nerve

Author:

Saito Tomoko¹^ORCID,Saito Toshio²,Hashimoto Hiroya³^ORCID,Ogata Katsuhisa⁴,Kobayashi Michio⁵,Takada Hiroto⁶,Kuru Satoshi⁷,Kimura Takashi⁸,Nakamura Akinori⁹,Matsumura Tsuyoshi¹

Affiliation:

1. Department of Neurology National Hospital Organization, Osaka Toneyama Medical Center Osaka Japan

2. Division of Child Neurology, Department of Neurology National Hospital Organization, Toneyama Medical Center Osaka Japan

3. Core Laboratory, Nagoya City University Graduate School of Medical Sciences Clinical Research Management Center, Nagoya City University Hospital Nagoya Japan

4. Department of Neurology National Hospital Organization, Higashisaitama National Hospital Saitama Japan

5. Department of Neurology National Hospital Organization, Akita National Hospital Akita Japan

6. Department of Neurology National Hospital Organization, Aomori National Hospital Aomori Japan

7. Department of Neurology National Hospital Organization, Suzuka National Hospital Suzuka Japan

8. Department of Neurology National Hospital Organization, Asahikawa Medical Center Asahikawa Japan

9. Department of Clinical Research National Hospital Organization, Matsumoto Medical Center Nagano Japan

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Neurology (clinical),Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mus.27761

Reference18 articles.

1. World Muscle Society.Covid‐19 and people with neuromuscular disorders: World Muscle Society position and advice.https://www.worldmusclesociety.org/file/ec4c36f3-8ce1-4762-981 e-a9b81823fd8a/WMS%20covid-19%20advice%2028-03-2020%201800.pdf. Accessed October 1 2021.

2. Morbidity, Clinical Course and Vaccination against SARS-CoV-2 Virus in Patients with Duchenne Muscular Dystrophy: A Patient Reported Survey

3. mRNA intramuscular vaccination produces a robust IgG antibody response in advanced neuromuscular disease

4. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

5. Ministry of Health Labour and Welfare. Health status survey after the first inoculation of the new corona vaccine.https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_kenkoujoukyoutyousa.html. Accessed October 1 2021.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends;Biomarker Research;2024-08-31

2. Primary Care Considerations for Individuals with Duchenne Muscular Dystrophy;2024

3. Myotonic dystrophy type 1 in the COVID-19 era;Neurological Sciences;2023-05-08

4. Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases;Human Vaccines & Immunotherapeutics;2023-01-02